PF-Atlas › Clinical Trials › NCT05668741
A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis
VX-522 mRNA therapy · Phase 1
Registry ID
NCT05668741
Phase
Phase 1
Status
Active, not recruiting
Drug / intervention
VX-522 mRNA therapy
Sponsor
Vertex Pharmaceuticals Incorporated
Start
2023-02-27
Enrollment
26
Locations
26
About this trial
The purpose of this study is to evaluate the safety, and tolerability and efficacy of VX-522 in participants 18 years of age and older with cystic fibrosis and a cystic fibrosis transmembrane conductance regulator (CFTR) genotype not responsive to CFTR modulator therapy.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT05668741 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.